肿瘤细胞治疗研究
英文原题：Cancer therapy-related cardiac dysfunction and the role of cardiovascular imaging: systemic review and opinion paper from the Working Group on Cardio-Oncology of the Korean Society of Cardiology.
Cancer therapy-related cardiac dysfunction and the role of cardiovascular imaging: systemic review and opinion paper from the Working Group on Cardio-Oncology of the Korean Society of Cardiology.
心脏肿瘤学是一个关键领域，因为心血管毒性作为抗癌治疗副作用的重要性日益凸显。
肿瘤心脏病学是一个关键领域，因为心血管毒性作为抗癌治疗副作用的重要性日益增加。癌症治疗相关心功能障碍（CTRCD）是一种与心血管毒性相关的常见病症，需要有效的预测、监测、管理和追踪策略。这篇综合性综述探讨了 CTRCD 的定义和风险分层，探索了抗癌治疗期间的监测方法，并重点介绍了与各种癌症治疗相关的特定心血管毒性。这些治疗包括蒽环类药物、HER2 靶向药物、血管内皮生长因子抑制剂、免疫检查点抑制剂、CAR-T 细胞疗法和TIL（肿瘤浸润淋巴细胞）疗法。结合韩国数据，本综述提供了对 CTRCD 管理中区域差异的见解。通过结合心血管影像学和生物标志物的系统性随访，可以更好地理解和管理 CTRCD，优化癌症患者和幸存者的心血管健康。
Cardio-oncology is a critical field due to the escalating significance of cardiovascular toxicity as a side effect of anticancer treatments. Cancer therapy-related cardiac dysfunction (CTRCD) is a prevalent condition associated with cardiovascular toxicity, necessitating effective strategies for prediction, monitoring, management, and tracking. This comprehensive review examines the definition and risk stratification of CTRCD, explores monitoring approaches during anticancer therapy, and highlights specific cardiovascular toxicities linked to various cancer treatments. These include anthracyclines, HER2-targeted agents, vascular endothelial growth factor inhibitors, immune checkpoint inhibitors, chimeric antigen receptor T-cell therapies, and tumor-infiltrating lymphocytes therapies. Incorporating the Korean data, this review offers insights into the regional nuances in managing CTRCD. Using systematic follow-up incorporating cardiovascular imaging and biomarkers, a better understanding and management of CTRCD can be achieved, optimizing the cardiovascular health of both cancer patients and survivors.
MEMBER ACCOUNT
登录成功会直接打开下一页。
